GLP-1 agonist treatment: implications for diabetic retinopathy screening

Lakshminarayanan Varadhan; Tracy Humphreys; Christian Hariman; Adrian B Walker; George I Varughese

doi:10.1016/j.diabres.2011.08.017

GLP-1 agonist treatment: implications for diabetic retinopathy screening

Diabetes Res Clin Pract. 2011 Dec;94(3):e68-71. doi: 10.1016/j.diabres.2011.08.017. Epub 2011 Sep 8.

Authors

Lakshminarayanan Varadhan¹, Tracy Humphreys, Christian Hariman, Adrian B Walker, George I Varughese

Affiliation

¹ Department of Diabetes and Endocrinology, University Hospital of North Staffordshire NHS Trust, Springfield Unit, North Buildings, Stoke-on-Trent ST4 6QG, United Kingdom.

PMID: 21906831
DOI: 10.1016/j.diabres.2011.08.017

Abstract

Rapid improvement in glycaemic control induced by GLP-1 agonist therapy could be yet another illustration of transient or permanent progression of diabetic retinopathy, similar to documented examples such as pregnancy and continuous subcutaneous insulin infusion. Specific guidelines would be needed to monitor this paradoxical phenomenon during treatment with GLP-1 agonists.

MeSH terms

Adult
Aged
Diabetes Complications / diagnosis
Diabetes Complications / drug therapy*
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Retinopathy / diagnosis*
Diabetic Retinopathy / etiology
Female
Glucagon-Like Peptide 1 / agonists*
Glucagon-Like Peptide 1 / therapeutic use*
Humans
Insulin Infusion Systems
Male
Mass Screening
Middle Aged
Pregnancy
Pregnancy in Diabetics / diagnosis*
Pregnancy in Diabetics / etiology
Prognosis
Retrospective Studies

Substances

Glucagon-Like Peptide 1